Sangamo Therapeutics (SGMOQ) Change in Acquisitions & Divestments (2010 - 2024)

Sangamo Therapeutics has reported Change in Acquisitions & Divestments for 15 years, with the latest figure at $34.7 million in Q1 2024.

• On a quarterly basis, Change in Acquisitions & Divestments fell 57.73% year-over-year to $34.7 million in Q1 2024; TTM through Dec 2024 was $34.7 million, a 83.81% decrease from a year earlier, with the FY2024 full-year figure at $34.7 million, down 83.81% from the prior year.
• Change in Acquisitions & Divestments was $34.7 million for Q1 2024 at Sangamo Therapeutics, up from $20.6 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $186.5 million in Q3 2021, with the low at $20.6 million in Q4 2023.
• Average Change in Acquisitions & Divestments over 5 years is $89.5 million, with a median of $82.2 million recorded in 2023.
• The sharpest annual moves came in 2020 and 2021: Change in Acquisitions & Divestments tumbled 81.79% in 2020, then surged 250.6% in 2021.
• Over 5 years, Change in Acquisitions & Divestments stood at $109.5 million in 2020, then retreated by 14.85% to $93.3 million in 2021, then increased by 6.79% to $99.6 million in 2022, then tumbled by 79.27% to $20.6 million in 2023, then jumped by 68.25% to $34.7 million in 2024.
• The last three Change in Acquisitions & Divestments figures came in at $34.7 million (Q1 2024), $20.6 million (Q4 2023), and $47.8 million (Q3 2023), per Business Quant data.